Compare Summit Therapeutics Inc (SMMT) vs Seagate Technology Holdings PLC (STX) Price & Performance

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.

STX trades at $904.38, up 6.49% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a net income margin of 26.11% and high ROE of 371.53%, though valuation ratios like P/E of 65.06 appear elevated. Recent news highlights AI-driven storage demand and HAMR technology advancements fueling growth, with revenue projected to rise to $12.2B in 2026.

Outlook is positive due to AI infrastructure demand and earnings momentum, but risks include high debt levels and valuation concerns. Analysts are bullish with a consensus price target of $1,130, suggesting upside potential, though investors should monitor execution risks and market volatility.